Press "Enter" to skip to content

The Direct Investment Fund ensures that the authorization to combine booster vaccines in the US confirms the effectiveness of Sputnik V

The Russian Direct Investment Fund (RDIF) interprets the fact that the combinations have been authorized by the US Food and Drug Administration (FDA) as corroboration of the success of the Sputnik V vaccine. of drugs against the coronavirus, which allows people already immunized to receive a different vaccine as a booster dose than the one they were initially given.

As indicated by the Fund this Thursday in a statement, Sputnik V combines human adenovirus serotype 26 as the first component and human adenovirus serotype 5 as the second component, an approach that “has been successful against the coronavirus, as it was confirmed that Sputnik V has a total efficacy of 91.4%, so it provides strong and long-lasting immunity. “

RDIF is one of the world leaders in the study of the combination of different vaccines. In December 2020, it established a collaboration with AstraZeneca to study the efficacy of combining the Oxford vaccine with the first component of Sputnik V and its single-dose version, Sputnik Light. Studies demonstrate “the high safety and immunogenicity profile of the combination,” notes the Fund.

In this regard, he points out that Sputnik Light is an efficient universal booster for other vaccines against covid-19. “Preliminary results of the study in Argentina on heterologous regimens that combine Sputnik Light with other vaccines produced by AstraZeneca, Sinopharm, Moderna and Cansino applied to more than 1,000 subjects indicate that Sputnik Light is an effective universal booster for these vaccines. Every ‘ vaccine cocktail ‘with the Sputnik Light provided a higher level of antibodies on day 14 after the application of the second dose compared to the original homogeneous regimens “, indicates the RDIF, which highlights” the high safety profile “of the vaccine Russian.

“Russia was a leader in the use of the vaccine combination approach (application of different vaccines with Sputnik V at the center of the initiative) and was the first country to offer vaccine alliances to other manufacturers. Trials are being successfully conducted combining the first component of Sputnik V (the single-dose Sputnik Light vaccine) with other vaccines. Sputnik Light has produced strong results in terms of safety and immunogenicity in pooled studies, showing that it is a universal booster and one of the best solutions to inoculate people who have already received other vaccines, “the statement cited the executive director of the RDIF, Kirill Dmitriev.

Article Source

Disclaimer: This article is generated from the feed and not edited by our team.